Risk factors assessment and surgical strategies of placenta accreta spectrum

doi:10.3877/cma.j.issn.2095-3259.2023.03.007

Abstract

Abstract:

Placenta accreta spectrum (PAS) disorders are severe maternal complications that can lead to life-threatening outcomes. The incidence of PAS has been increasing year by year, making it a substantial challenge for obstetricians. Improving the quality of obstetric care to enhance maternal outcomes in an evidence-based approach stands as a shared objective on a global scale. This article focuses on the key issues surrounding PAS, including the risk factors for PAS, preoperative risk stratification for PAS, and optimizing surgical strategies to improve clinical outcomes.

Key words: Placenta accreta, Risk assessment, Hysterectomy, Conservative treatment

Zhirong Guo, Jingmei Ma. Risk factors assessment and surgical strategies of placenta accreta spectrum[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2023, 12(03): 151-154.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhckjjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3259.2023.03.007

https://zhckjjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I03/151

References 33

[1]	Silver RM, Branch DW. Placenta accreta spectrum[J]. N Engl J Med 2018，378(16)：1529-1536.
[2]	Matsuzaki S, Mandelbaum RS, Sangara RN, et al. Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States[J]. Am J Obstet Gynecol，2021，225(5)：534.e1-534.e38.
[3]	Ming Y, Zeng X, Zheng T, et al. Epidemiology of placenta accreta spectrum disorders in Chinese pregnant women: a multicenter hospital-based study[J]. Placenta，2022，126：133-139.
[4]	Jauniaux E, Chantraine F, Silver RM, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology[J]. Int J Gynaecol Obstet，2018，140(3)：265-273.
[5]	中华医学会围产医学分会，中华医学会妇产科学分会产科学组. 胎盘植入诊治指南(2015)[J/OL]. 中华产科急救电子杂志，2016，5(1)：26-31.
[6]	Jauniaux E, Burton GJ. Pathophysiology of placenta accreta spectrum disorders: a review of current findings[J]. Clin Obstet Gynecol，2018，61(4)：743-754.
[7]	Ma J, Liu Y, Guo Z, et al. The diversity of trophoblast cells and niches of placenta accreta spectrum disorders revealed by single-cell RNA sequencing[J]. Front Cell Dev Biol，2022，10：1-16.
[8]	Silver RM. Abnormal placentation: placenta previa, vasa previa, and placenta accreta[J]. Obstet Gynecol，2015，126(3)：654-668.
[9]	Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries[J]. BJOG，2016，123(8)：1348-1355.
[10]	Al-Lami RA, Salih SM, Sibai BM. In vitro fertilization as an independent risk factor for placenta accreta spectrum[J]. Am J Obstet Gynecol，2021，225(6)：699.
[11]	Guo Z, Han X, Zheng W, et al. Placenta accreta spectrum among multiple gestation: a retrospective analysis based on a Chinese population[J]. Front Endocrinol (Lausanne)，2022，13：1-7.
[12]	Miller HE, Leonard SA, Fox KA, et al. Placenta accreta spectrum among women with twin gestations[J]. Obstet Gynecol，2021，137(1)：132-138.
[13]	Cali G, Forlani F, Lees C, et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders[J]. Ultrasound Obstet Gynecol，2019，53(6)：752-760.
[14]	Zheng W, Zhang H, Ma J, et al. Validation of a scoring system for prediction of obstetric complications in placenta accreta spectrum disorders[J]. J Matern Fetal Neona，2022，35(21)：4149-4155.
[15]	Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, et al. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders[J]. Int J Gynaecol Obstet，2019，146(1)：20-24.
[16]	Meng X, Xie L, Song W. Comparing the diagnostic value of ultrasound and magnetic resonance imaging for placenta accreta: a systematic review and meta-analysis[J]. Ultrasound Med Biol，2013，39(11)：1958-1965.
[17]	Familiari A, Liberati M, Lim P, et al. Diagnostic accuracy of magnetic resonance imaging in detecting the severity of abnormal invasive placenta: a systematic review and meta-analysis[J]. Acta Obstet Gynecol Scand，2018，97(5)：507-520.
[18]	Jauniaux E, Bhide A, Kennedy A, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: prenatal diagnosis and screening[J]. Int J Gynaecol Obstet，2018，140(3)：274-280.
[19]	Phipps EA, Thadhani R, Benzing T, et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapies[J]. Nat Rev Nephrol，2019，15(5)：275-289.
[20]	Guo Z, Yang H, Ma J. Maternal circulating biomarkers associated with placenta accreta spectrum disorders[J]. Chin Med J (Engl)，2023，136(8)：995-997.
[21]	Afshar Y, Dong J, Zhao P, et al. Circulating trophoblast cell clusters for early detection of placenta accreta spectrum disorders[J]. Nat Commun，2021，12(1)：1-14.
[22]	Guo Z, Han X, Zhang H, et al. Association between pre-delivery coagulation indicators and invasive placenta accreta spectrum[J]. Clin Appl Thromb Hemost，2022，28：1-8.
[23]	Allen L, Jauniaux E, Hobson S, et al. FIGO consensus guidelines on placenta accreta spectrum disorders: nonconservative surgical management[J]. Int J Gynaecol Obstet，2018，140(3)：281-290.
[24]	Sentilhes L, Seco A, Azria E, et al. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study[J]. Am J Obstet Gynecol，2022，226(6)：839.e1-839.e24.
[25]	Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline No. 27a[J]. BJOG，2019，126(1)：e1-e48.
[26]	Hobson SR, Kingdom JC, Murji A, et al. No. 383-Screening, diagnosis, and management of placenta accreta spectrum disorders[J]. J Obstet Gynaecol Can，2019，41(7)：1035-1049.
[27]	Matsuo K, Youssefzadeh AC, Mandelbaum RS, et al. Hospital surgical volume-outcome relationship in caesarean hysterectomy for placenta accreta spectrum[J]. BJOG，2022，129(6)：986-993.
[28]	Bhide A. BJOG mini commentary on placenta accreta spectrum-variations in clinical practice and maternal morbidity between UK and France: a population-based comparative study[J]. BJOG，2022，129(10)：1686.
[29]	Wang Q, Ma J, Zhang H, et al. Conservative management versus cesarean hysterectomy in patients with placenta increta or percreta[J]. J Matern Fetal Neonatal Med，2022，35(10)：1944-1950.
[30]	Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta[J]. Obstet Gynecol，2010，115(3)：526-534.
[31]	Sentilhes L, Kayem G, Silver RM. Conservative management of placenta accreta spectrum[J]. Clin Obstet Gynecol，2018，61(4)：783-794.
[32]	Sentilhes L, Kayem G, Ambroselli C, et al. Fertility and pregnancy outcomes following conservative treatment for placenta accreta[J]. Hum Reprod，2010，25(11)：2803-2810.
[33]	Grover B, Einerson BD, Keenan KD, et al. Patient-reported health outcomes and quality of life after peripartum hysterectomy for placenta accreta spectrum[J]. Am J Perinatol，2022，39(3)：281-287.

Please choose a citation manager

Content to export